Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: section IIb outcomes Individuals who've been through big surgical treatment which includes pituitary surgical procedure inside 1 thirty day period of screening or who may have any significant surgical treatments planned over the research time period Name https://emilioucim20630.getblogs.net/62375538/gsk-650394-fundamentals-explained